|Articles|December 20, 2010

Facing Type 2 Diabetes in the Healthcare Reform Era [CME/CPE]
Volume 16
Issue 11 Suppl

Facing Type 2 Diabetes in the Healthcare Reform Era

Download PDF: Facing Type 2 Diabetes in the Healthcare Reform Era

Articles in this issue

over 15 years ago

Article

SECTION 1: The Clinical Challenges of Diabetes Management

over 15 years ago

Article

SECTION 3: Value-Based Insurance Design for Diabetes Mellitus: Approaches to Optimal Pharmacoeconomic Implementation

over 15 years ago

Article

Participating Faculty

over 15 years ago

Article

Disclosures

over 15 years ago

Article

SECTION 2: Diabetes Management Challenges Facing the Patient, Physician, and Payer

over 15 years ago

Article

Facing Type 2 Diabetes in the Healthcare Reform Era

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Facing Type 2 Diabetes in the Healthcare Reform Era

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

Expanding Community Access to CAR T, Bispecific Therapies in Multiple Myeloma: Peter Forsberg, MD

Philadelphia Employer Coalition Podcast Targets GLP-1s, Cancer Care

FDA Panel Backs 6 Peptides for Compounding

A Look at PBM Reform and Transparency: Payer, Provider and Patient Impact

Facing Type 2 Diabetes in the Healthcare Reform Era

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Approves Lutetium Lu 177 for Earlier-Stage Prostate Cancer

Atacicept Becomes First BAFF/APRIL Inhibitor Approved for IgA Nephropathy: Richard Lafayette, MD

Expanding Community Access to CAR T, Bispecific Therapies in Multiple Myeloma: Peter Forsberg, MD

Philadelphia Employer Coalition Podcast Targets GLP-1s, Cancer Care

FDA Panel Backs 6 Peptides for Compounding